All In Biotech

Drug Trial Radar · NCT00868166

Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS

Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole

Last checked: Nov 20, 2026Latest source record: Feb 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 512 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

512

Actual

Start

Apr 30, 2009

Primary completion

Sep 30, 2011

Study completion Sep 30, 2011

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
European Commission
First posted
Mar 24, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month survival rate.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • OlesoximeDrug

    2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid

  • Placebo ComparatorDrug

    2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid

  • RiluzoleDrug

    Riluzole given as add-on therapy 50mg bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival Rate at 18 MonthsTime frame: From the date of randomization until the date of death or last follow-up censored at 18 months (548 days)

Locations

15 sites in 5 countries. Site status is shown where the registry gives one.

  • University Hospital Gasthuisberg - Dept Neurology - Herestraat 49

    Leuven, Belgium

  • HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel

    Bron, France

  • CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement

    Lille, France

  • Centre SLA Limoges - Service de Neurologie

    Limoges, France

  • Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires

    Marseille, France

  • Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac

    Montpellier, France

  • CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA

    Nice, France

  • Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux

    Paris, France

  • Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen

    Berlin, Germany

  • Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg

    Halle, Germany

  • Neurologische Klinik Medizinische Hochschule

    Hanover, Germany

  • Universitäts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik

    Ulm, Germany

  • Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10

    Madrid, Spain

  • King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry

    London, United Kingdom

  • Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.